ETFs & Funds
data likely to b > Abraxane
. Abrax trial began 3/09. Near end of trial on 9/11, protocol changed and added 210 pts
Likely had to add pts because initial
data on 630 pts was not good. If
#s good, absolutely no reason to add pts to trial
Th-302 targets hypoxic niche, which should also kill CSCs.
OT- That was a bummer yesterday that Bapi got cancelled. I really thought the Apo4 non-carriers would have some positive news.
Add a reply...
Latest StockTalks »
people get THLD breaking news and analysis by email alert.
Get email alerts on THLD »
Threshold Pharmaceuticals, Inc.
Get latest price
From other sites
Threshold Pharmaceuticals’ stock plunges after drug trial disappoints
at MarketWatch.com (Dec 7, 2015)
Threshold Pharmaceuticals : Announces Presentation and Webcast at the Stifel 2015 Healthcare Conference
at 4-traders.com (Nov 11, 2015)
19 Lesser-Known Biotech Stocks With Robust Drug Pipelines
at Benzinga.com (Dec 31, 2014)
Stocks to Watch: WFC, TSLA, NFLX & More
at CNBC.com (Sep 17, 2012)
Movers & Shakers: Monday’s biggest gaining and declining stocks
at MarketWatch.com (Sep 17, 2012)